β-arrestin2 mediates β-2 adrenergic receptor signaling inducing prostate cancer cell progression

Oncology Reports

Volumn 26, Issue 6, 2011, Pages 1471-1477

  Zhang, Penghui ^a   He, Xiaoyan ^a   Tan, Junjie ^a   Zhou, Xiaoyan ^a   Zou, Lin ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

2 adrenergic receptor; arrestin2; Prostate cancer; Src

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN 2; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE P60;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; COMPLEX FORMATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ARRESTINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC AMP; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; ISOPROTERENOL; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEIN-TYROSINE KINASES; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 80053526319     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1417     Document Type: Article

References (42)

1. Schuller HM: Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 19: 655-671, 2008.
2. Thaker PH, Lutgendorf SK and Sood AK: The neuroendocrine impact of chronic stress on cancer. Cell Cycle 6: 430-433, 2007. (Pubitemid 46393445)
3. Johnson M: The beta-adrenoceptor. Am J Respir Crit Care Med 158: S146-S153, 1998.
4. Goepel M, Wittmann A, Rubben H and Michel MC: Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol Res 25: 199-206, 1997. (Pubitemid 27252798)
5. Wisler JW, DeWire SM, Whalen EJ, et al: A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 104: 16657-16662, 2007. (Pubitemid 350211072)
6. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004. (Pubitemid 38443417)
7. Sastry KS, Karpova Y, Prokopovich S, et al: Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 282: 14094-14100, 2007. (Pubitemid 47100469)
8. Marchetti B, Poulin R, Plante M and Labrie F: Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. J Steroid Biochem 31: 411-419, 1988.
9. Ramos-Jimenez J, Soria-Jasso LE, Lopez-Colombo A, Reyes-Esparza JA, Camacho J and Arias-Montano JA: Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol 73: 814-823, 2007. (Pubitemid 46227335)
10. Kue PF, Taub JS, Harrington LB, Polakiewicz RD, Ullrich A and Daaka Y: Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells. Int J Cancer 102: 572-579, 2002. (Pubitemid 35334463)
11. Sivashanmugam P, Tang L and Daaka Y: Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem 279: 21154-21159, 2004. (Pubitemid 38656518)
12. Lee LF, Guan J, Qiu Y and Kung HJ: Neuropeptide-induced androgen independence in prostate cancer cells: roles of non-receptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 21: 8385-8397, 2001. (Pubitemid 33108599)
13. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF and DaakaY: Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 63: 2037-2041, 2003. (Pubitemid 36538604)
14. Carie AE and Sebti SM: A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 26: 3777-3788, 2007. (Pubitemid 46878138)
15. Kobayashi H, Narita Y, Nishida M and Kurose H: Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK. Cell Signal 17: 1248-1253, 2005. (Pubitemid 40982615)
16. Huang J, Sun Y and Huang XY: Distinct roles for Src tyrosine kinase in beta2-adrenergic receptor signaling to MAPK and in receptor internalization. J Biol Chem 279: 21637-21642, 2004. (Pubitemid 38656575)
17. Fan G, Shumay E, Malbon CC and Wang H: c-Src tyrosine kinase binds the beta 2-adrenergic receptor via phospho-Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization. J Biol Chem 276: 13240-13247, 2001.
18. Pierce KL, Maudsley S, Daaka Y, Luttrell LM and Lefkowitz RJ: Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and non-sequestering G protein-coupled receptors. Proc Natl Acad Sci USA 97: 1489-1494, 2000. (Pubitemid 30118468)
19. Wu WK, Wong HP, Luo SW, et al: 4-(Methylnitrosamino)-1-(3-pyridyl)-1- butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors. Cancer Res 65: 5272-5277, 2005. (Pubitemid 40827338)
20. Shenoy SK, Drake MT, Nelson CD, et al: beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281: 1261-1273, 2006.
21. Lohse MJ, Andexinger S, Pitcher J, et al: Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. J Biol Chem 267: 8558-8564, 1992.
22. Han M, Gurevich VV, Vishnivetskiy SA, Sigler PB and Schubert C: Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane translocation. Structure 9: 869-880, 2001. (Pubitemid 32913504)
23. Shenoy SK and LefkowitzRJ: Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 375: 503-515, 2003. (Pubitemid 37433499)
24. Oakley RH, Laporte SA, Holt JA, Barak LS and Caron MG: Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 274: 32248-32257, 1999.
25. Oakley RH, Laporte SA, Holt JA, Caron MG and Barak LS: Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275: 17201-17210, 2000. (Pubitemid 30398969)
26. Perry SJ and Lefkowitz RJ: Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 12: 130-138, 2002. (Pubitemid 34164652)
27. Ferguson SS, Zhang J, Barak LS and Caron MG: Molecular mechanisms of G protein-coupled receptor desensitization and resensitization. Life Sci 62: 1561-1565, 1998. (Pubitemid 28210241)
28. Shenoy SK and Lefkowitz RJ: Seven-transmembrane receptor signaling through beta-arrestin. Sci STKE 2005: cm10, 2005.
29. Wang P, Gao H, Ni Y, et al: Beta-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem 278: 6363-6370, 2003. (Pubitemid 36800895)
30. Chen W, Kirkbride KC, How T, et al: Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 301: 1394-1397, 2003. (Pubitemid 37075818)
31. Wang Y, Tang Y, Teng L, Wu Y, Zhao X and PeiG: Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 7: 139-147, 2006. (Pubitemid 43135879)
32. Zou L, Yang R, Chai J and PeiG: Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis. FASEB J 22: 355-364, 2008. (Pubitemid 351227345)
33. Thomas SM and Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609, 1997. (Pubitemid 28034534)
34. Parker RC, Varmus HE and Bishop JM: Expression of v-src and chicken c-src in rat cells demonstrates qualitative differences between pp60v-src and pp60c-src. Cell 37: 131-139, 1984. (Pubitemid 14079844)
35. Hunter T and Cooper JA: Protein-tyrosine kinases. Annu Rev Biochem 54: 897-930, 1985. (Pubitemid 15073667)
36. Luttrell LM, Hawes BE, Van Biesen T, Luttrell DK, LansingTJ and Lefkowitz RJ: Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gβγ subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 271: 19443-19450, 1996. (Pubitemid 26271617)
37. Simonson MS, Wang Y and Herman WH: Nuclear signaling by endothelin-1 requires Src protein-tyrosine kinases. J Biol Chem 271: 77-82, 1996. (Pubitemid 26026561)
38. Schieffer B, Drexler H, Ling BN and Marrero MB: G protein-coupled receptors control vascular smooth muscle cell proliferation via pp60c-src and p21ras. Am J Physiol 272: C2019-C2030, 1997.
39. Postma FR, Hengeveld T, Alblas J, et al: Acute loss of cell-cell communication caused by G protein-coupled receptors: a critical role for c-Src. J Cell Biol 140: 1199-1209, 1998. (Pubitemid 28128879)
40. Luttrell LM, Ferguson SS, Daaka Y, et al: Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283: 655-661, 1999.
41. Violin JD, Ren XR and Lefkowitz RJ: G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer. J Biol Chem 281: 20577-20588, 2006. (Pubitemid 44065829)
42. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM and DuBois RN: Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103: 1492-1497, 2006. (Pubitemid 43191193)